No Data
Express News | Enlivex Therapeutics Ltd - No Serious Adverse Reactions Reported in Phase I Safety Run-in
All You Need to Know About Enlivex Therapeutics (ENLV) Rating Upgrade to Buy
H.C. Wainwright Maintains Enlivex Therapeutics(ENLV.US) With Buy Rating, Maintains Target Price $6
Enlivex Therapeutics Financials Indicate Net Loss
Enlivex Therapeutics Price Target Announced at $13.00/Share by EF Hutton
Express News | Enlivex Receives Israeli Ministry Of Health Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis